Latest From DiaSorin SPA
November’s approvals include the US FDA approval of Medtronic’s In.Pact AV paclitaxel-coated balloon, for the treatment of arteriovenous access in patients with end-stage renal disease, and a CE mark that expands the indication for Edwards’ Sapien 3 TAVR device to include patients at low-risk during surgery.
October’s approvals include the US FDA approval of Myriad’s myChoice CDx companion diagnostic for GlaxoSmithKline’s ovarian cancer drug and the approval or Medtronic’s Valiant Navion thoracic stent graft system in Japan.
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
Sanofi signed a $2bn deal with DiCE Molecules to develop small molecules against targets previously addressed by biologics; Toshiba sold its diagnostics and medical imaging division to Canon for $6bn. Debt offerings dominated biopharma and device financings.
In Vitro Diagnostics
- Chemistry, Immunoassay
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- DiaSorin SPA
- Senior Management
Carlo Rosa, CEO
Piergiorgio Pedron, SVP, CFO
Chen Even, Chief Commercial Officer
- Contact Info
Phone: (39) 0161 487 526
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.